

The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2000

Professor Victor J. Dzau

Hersey Professor of the Theory and Practice of Physic at
Harvard Medical School, Boston, Mass. USA

**Cardiovascular genetic manipulation-what are
the limits?**



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2003

Professor Valentin Fuster

Mount Sinai Medical Centre, New York, USA

Plaque instability and the role of MRI: The cutting edge of knowledge




THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2005

Dr. Peter Libby

Brigham and Women's Hospital in Boston, MA., USA

The inflammatory hypothesis for atherosclerosis



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2006

Professor Nanette Wenger

Division of Cardiology, Emory University School of Medicine,
Atlanta, USA

**Coronary heart disease in women 2006:
problems, progress and prospects**



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2007

Professor Eduardo Marban

Johns Hopkins University, Maryland, USA

Looking to the future: gene therapy for cardiac arrhythmias?



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2008

Professor Eric Topol

Scripps Translational Research Institute, La Jolla, California, USA

The impact of genomics on the cardiovascular system: where are the limits?



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2009

Professor Bernard Gersh

Mayo Clinic, Rochester, USA

Challenges in chronic stable angina: medical management, stent or surgery – are we at the limits?



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2010

Dr. Kenneth Chien

**Massachusetts General Hospital & Harvard Medical School,
Boston, USA**

**Novel cellular therapies to prevent the onset and
progression of heart failure**




THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2011

Professor Salim Yusuf

McMaster University and Hamilton Health Sciences, Ontario,
Canada

**The limits of anti-coagulation – will they ever be
reached?**



THE LANCET



The Hatter Award Annual Lecture



2012

Professor John Camm

St Georges Hospital, University of London, UK

Drugs against AF:- are we at the limits?



THE LANCET



The Hatter Award Annual Lecture



2013

Professor Morris Brown

University of Cambridge, UK

Blood pressure control in diabetes: what are the limits, what are the drugs and how are they defined?



THE LANCET



The Hatter Award Annual Lecture



2014

Professor Derick Raal

University of the Witwatersrand, South Africa


The future beyond statins: novel lipid-lowering drugs



THE LANCET



The Hatter Award Annual Lecture



2015

Professor Solomon Benatar

University of Cape Town, South Africa

Rationing medical care: defining the limits



THE LANCET



The Hatter Award Annual Lecture



2016

Professor Bernard Gersh

Mayo Clinic, Rochester, USA

The Epidemic of Atrial Fibrillation: Is it a vascular disease?



THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2017

Professor C Noel Bairey Merz

Cedars-Sinai Medical Centre, Los Angeles, USA

**Is it time to look at microvascular angina?
Are these the new limits?**




THE LANCET



The Hatter Award Annual Lecture

at the limits CARDIOLOGY, DIABETES & NEPHROLOGY



2018

Professor Philippe Menasché

University Paris-Descartes, Paris, France

Looking beyond stem cells



THE LANCET



The Hatter Award Annual Lecture



2019

Professor Milton Packer

Baylor University Medical Center, Dallas, Texas, USA

Heart failure – are there limits to anti-diabetic therapy with SGLT2 inhibitors?



THE LANCET

